Developments: Pharmaceutical policy in the UK

For many years drug price regulation posed few public management problems. However, the overall NHS drugs budget has been increasing by almost 9% per annum over the past decade. Governments in the 1990s tried to control this growth by introducing new pharmaceutical policy instruments. This has led to an element of instability in the regulation of the pharmaceutical industry, which is affecting NHS financial programming, as well as R&D investment decisions by companies. This article recommends the creation of an office for drug regulation (an ‘OFDRUG’) to reintroduce stability into pharmaceutical policy.